ENTEROME

Paris, France

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

$19.0M raised

Jun 2025

Venture - Series Unknown

Top Investors

European Investment BankOmnes CapitalSeventure PartnersBristol-Myers SquibbPrimo Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ENTEROME raised?

ENTEROME has raised $19.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2025.

Who are ENTEROME's investors?

ENTEROME's investors include European Investment Bank, Omnes Capital, Seventure Partners, Bristol-Myers Squibb, Primo Capital.

Where is ENTEROME headquartered?

ENTEROME is headquartered in Paris, France.

What does ENTEROME do?

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

What stage is ENTEROME at?

ENTEROME is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 12, 2025.

MLA

"ENTEROME — Funding & Investors." VCBacked, June 12, 2025, https://www.vcbacked.co/company/enterome. Accessed June 4, 2026.

APA

VCBacked. (2025). ENTEROME — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/enterome

Wikipedia (cite web)

{{cite web |title=ENTEROME — Funding & Investors |url=https://www.vcbacked.co/company/enterome |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 12, 2025.